Codexis logo

CodexisNASDAQ: CDXS

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

22 April 2010

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$342.60 M
-85%vs. 3y high
61%vs. sector
-vs. 3y high
-vs. sector
-67%vs. 3y high
80%vs. sector
-77%vs. 3y high
62%vs. sector

Price

after hours | 3 min ago
$4.21+$0.28(+7.12%)

Dividend

No data over the past 3 years
$12.83 M$27.41 M
$12.83 M-$20.64 M

Analysts recommendations

Institutional Ownership

CDXS Latest News

Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference
globenewswire.com19 November 2024 Sentiment: -

REDWOOD CITY, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will attend the Piper Sandler 36th Annual Healthcare Conference, being held December 3-5, 2024, in New York, New York.

Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics
globenewswire.com11 November 2024 Sentiment: POSITIVE

—Spotlight Presentation to showcase four routes of synthesis of an approved siRNA therapeutic asset— —Joint poster presentation with Bachem to compare Codexis double-stranded RNA ligase to wild-type enzymes— —Management to host conference call on Thursday, November 14 to discuss data— REDWOOD CITY, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will demonstrate real-world application of its enzymatic synthesis platform via three presentations at the upcoming TIDES Europe annual meeting, being held November 12-14, 2024, in Hamburg, Germany.

Codexis Announces New Employment Inducement Grants
globenewswire.com08 November 2024 Sentiment: POSITIVE

REDWOOD CITY, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of an equity grant to one new employee as approved by the Compensation Committee of Codexis' Board of Directors. The newly hired employee received an equity award consisting of (i) options to purchase 50,000 shares of Codexis common stock and (ii) 15,000 restricted stock units (RSUs) as an inducement award under the company's 2024 Inducement Plan.

Codexis, Inc. (CDXS) Q3 2024 Earnings Call Transcript
seekingalpha.com31 October 2024 Sentiment: NEUTRAL

Codexis, Inc. (CDXS) Q3 2024 Earnings Call Transcript

Codexis (CDXS) Reports Q3 Loss, Tops Revenue Estimates
zacks.com31 October 2024 Sentiment: NEUTRAL

Codexis (CDXS) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.26 per share a year ago.

Codexis Announces Three siRNA Manufacturing Data Presentations at TIDES Europe Annual Meeting
globenewswire.com24 October 2024 Sentiment: POSITIVE

Oral Presentations to Highlight Results of Customer Collaborations using the ECO Synthesis™ Platform Oral Presentations to Highlight Results of Customer Collaborations using the ECO Synthesis™ Platform

Codexis Announces New Employment Inducement Grants
globenewswire.com14 October 2024 Sentiment: POSITIVE

REDWOOD CITY, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of equity grants to eight new employees as approved by the Compensation Committee of Codexis' Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 350,175 shares of Codexis common stock and (ii) 80,138 restricted stock units (RSUs) as inducement awards under the company's 2024 Inducement Plan. Included in this total are equity awards for Codexis' newly appointed Chief Financial Officer, Georgia Erbez. As part of her inducement to commence employment, Ms. Erbez was granted an option to purchase 300,000 shares of Company common stock and 50,000 shares of RSUs.

Codexis to Report Third Quarter 2024 Financial Results on October 31
globenewswire.com10 October 2024 Sentiment: POSITIVE

REDWOOD CITY, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the third quarter of 2024 on Thursday, October 31, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update.

Codexis Increases Cash Reserves and Enhances Management Team to Fuel Growth of Company
globenewswire.com02 October 2024 Sentiment: POSITIVE

Company raises $31 million through ATM, bringing cash runway into 2027 New additions to leadership in technical operations, finance and intellectual property prepare Codexis for the next phase of growth REDWOOD CITY, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced an increase in its cash reserves through capital raises totaling $31 million via the Company's existing at-the-market facility during the quarter ended September 30, 2024.

Codexis Licenses Genomics Life Science Enzyme Portfolio to Alphazyme LLC, part of Maravai LifeSciences
globenewswire.com01 October 2024 Sentiment: POSITIVE

Non-exclusive license includes HiFi DNA Polymerase, HiTemp Reverse Transcriptase, HiRev Isothermal Polymerase and other enzymes for genomics and diagnostic applications Non-exclusive license includes HiFi DNA Polymerase, HiTemp Reverse Transcriptase, HiRev Isothermal Polymerase and other enzymes for genomics and diagnostic applications

  • 1(current)

What type of business is Codexis?

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

What sector is Codexis in?

Codexis is in the Healthcare sector

What industry is Codexis in?

Codexis is in the Biotechnology industry

What country is Codexis from?

Codexis is headquartered in United States

When did Codexis go public?

Codexis initial public offering (IPO) was on 22 April 2010

What is Codexis website?

https://www.codexis.com

Is Codexis in the S&P 500?

No, Codexis is not included in the S&P 500 index

Is Codexis in the NASDAQ 100?

No, Codexis is not included in the NASDAQ 100 index

Is Codexis in the Dow Jones?

No, Codexis is not included in the Dow Jones index

When was Codexis the previous earnings report?

No data

When does Codexis earnings report?

The next expected earnings date for Codexis is 28 February 2025